Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetyGlobeNewsWire • 09/03/24
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsGlobeNewsWire • 08/26/24
FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentGlobeNewsWire • 08/01/24
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) TreatmentGlobeNewsWire • 07/25/24
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)Zacks Investment Research • 07/10/24
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingGlobeNewsWire • 06/20/24
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)Zacks Investment Research • 06/18/24
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsGlobeNewsWire • 06/12/24
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaGlobeNewsWire • 06/04/24
Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaGlobeNewsWire • 05/06/24
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023GlobeNewsWire • 04/29/24
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsGlobeNewsWire • 04/22/24
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsGlobeNewsWire • 04/10/24
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingGlobeNewsWire • 04/08/24